StockNews.com Initiates Coverage on MediciNova with 'Hold' Rating StockNews.com has started coverage on MediciNova, assigning a 'hold' rating to the biopharmaceutical firm. Meanwhile, D. Boral Capital reiterated its 'buy' rating and maintained a $9.00 price target. The company, specializing in treatments for serious diseases, recently reported quarterly earnings in line with expectations at ($0.06) per share.1